The mammalian target of rapamycin inhibitor RAD 001
The mammalian target of rapamycin inhibitor RAD 001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia by Philip Saunders, Adam Cisterne, Jocelyn Weiss, Kenneth F. Bradstock, and Linda J. Bendall haematol Volume 96(1): 69 -77 December 30, 2010 © 2011 by Ferrata Storti Foundation
RAD 001 synergizes with radiation in a dose-dependent manner to increase ALL cell death. Philip Saunders et al. Haematologica 2011; 96: 69 -77 © 2011 by Ferrata Storti Foundation
Synergistic killing of ALL cells by 16 μM RAD 001 and chemotherapeutic agents. Philip Saunders et al. Haematologica 2011; 96: 69 -77 © 2011 by Ferrata Storti Foundation
Synergistic cell death was caspase-dependent and p 53 -independent. Philip Saunders et al. Haematologica 2011; 96: 69 -77 © 2011 by Ferrata Storti Foundation
Synergistic cell death was partially mediated by activation of the JNK pathway. Philip Saunders et al. Haematologica 2011; 96: 69 -77 © 2011 by Ferrata Storti Foundation
Proteasome inhibitors synergize with RAD 001. Philip Saunders et al. Haematologica 2011; 96: 69 -77 © 2011 by Ferrata Storti Foundation
RAD 001 suppresses expression of p 53 and p 21 induced by cytotoxic agents. Philip Saunders et al. Haematologica 2011; 96: 69 -77 © 2011 by Ferrata Storti Foundation
- Slides: 7